share_log

Citigroup Maintains Neutral on Clover Health Investments, Raises Price Target to $1.5

Citigroup Maintains Neutral on Clover Health Investments, Raises Price Target to $1.5

花旗集团对三叶草健康投资保持中立,将目标股价上调至1.5美元
Benzinga ·  2023/08/11 09:25

Citigroup analyst Jason Cassorla maintains Clover Health Investments (NASDAQ:CLOV) with a Neutral and raises the price target from $1 to $1.5.

花旗集团分析师杰森·卡索拉将Clover Health Investments(纳斯达克股票代码:CLOV)维持中性,并将目标股价从1美元上调至1.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发